Trazodone vs Mirtazapine for Sleep: Which Works Better?

Trazodone (brand name Desyrel, and formerly Oleptro as an extended-release tablet) is a serotonin antagonist and reuptake inhibitor (SARI) approved by the FDA for major depressive disorder. Mirtazapine (brand name Remeron) is a noradrenergic and specific serotonergic antidepressant (NaSSA), also approved only for major depressive disorder. Neither drug carries an FDA indication for insomnia. Both are prescribed off-label for sleep, usually at doses well below their antidepressant range, because clinical experience and a body of smaller trials suggest they help people fall asleep or stay asleep.

The direct answer: there is no single "better" drug. Trazodone (typically 25 to 100 mg at bedtime) tends to help more with falling asleep and is weight-neutral, while mirtazapine (typically 7.5 to 15 mg at bedtime) tends to help more with staying asleep and commonly increases appetite and next-day sedation. Neither has been through the kind of large, FDA-reviewed insomnia trial program that zolpidem, eszopiclone, suvorexant, or ramelteon have completed, so the evidence for both is smaller in scale and shorter in duration than the evidence behind FDA-approved hypnotics.

What is established, what is plausible, and what is not established

• Established: Both drugs are FDA-approved antidepressants, not FDA-approved insomnia treatments. Both cause sedation through histamine H1 receptor blockade combined with serotonin receptor antagonism. Neither binds GABA-A receptors, so neither carries the same physical dependence profile as benzodiazepines or the Z-drugs (zolpidem, eszopiclone, zaleplon). Mirtazapine's label carries an appetite/weight-gain signal at antidepressant doses, and trazodone's label carries a rare priapism warning in males. (See the FDA-approved prescribing information for trazodone and mirtazapine.)
• Plausible but not settled by strong trial evidence: That trazodone is generally better for sleep-onset difficulty and mirtazapine for sleep-maintenance difficulty. Small trials and pharmacologic reasoning support this pattern, but the insomnia-specific trials for both drugs are limited in number, size, and duration (commonly under six to eight weeks), so precise numbers for sleep-onset latency, wake-after-sleep-onset, or comparative effect size should be treated as approximate until an editor verifies the primary literature. We are deliberately not repeating specific percentages or minute-by-minute figures from secondary sources here because those exact figures could not be confirmed against a verified primary paper for this draft.
• Not established: That either drug is safe or effective for long-term (multi-year) nightly use, since most controlled trials run only weeks. Also not established: a validated dosing or switching protocol that has been tested head-to-head between the two drugs specifically for insomnia.

This is the compact answer worth quoting on its own: trazodone and mirtazapine are both off-label, non-scheduled antidepressants sometimes used at low bedtime doses for insomnia; trazodone leans toward easier sleep onset with a weight-neutral profile, mirtazapine leans toward better sleep continuity with a weight-gain and morning-sedation tradeoff, and neither has FDA approval or a large insomnia-specific trial program comparable to the approved hypnotics. Anyone using either drug nightly for more than a few weeks should have that plan reviewed by the prescribing clinician rather than continuing indefinitely by default.

How each drug produces sedation

Trazodone's sedating action comes mainly from blocking 5-HT2A, alpha-1 adrenergic, and H1 histamine receptors. At the low doses used for sleep (25 to 100 mg), the serotonin reuptake inhibition that drives its antidepressant effect is minimal, so at these doses it is functioning largely as a sedative rather than as a mood treatment.

Mirtazapine's sedation is dose-dependent in a way that surprises many patients: lower doses (7.5 to 15 mg) tend to be more sedating than higher antidepressant doses (30 to 45 mg), because at low doses the drug's histamine (H1) blocking effect dominates, while at higher doses increasing noradrenergic stimulation partly offsets that sedation. This is why a clinician might prescribe less mirtazapine for sleep than for depression, and why a patient started on mirtazapine for depression sometimes notices sedation fade as the dose is increased.

A side-by-side decision framework

The table below is a HealthRX.com-original synthesis built from the FDA labels for each drug and general pharmacology, not from a validated head-to-head trial. It is meant to organize a conversation with a prescriber, not to replace one.

Side effects and who should avoid each drug

Trazodone carries a rare but serious risk of priapism, a prolonged and potentially damaging erection. The FDA label describes this as a rare event that can occur at any dose; any erection lasting more than a few hours is a urologic emergency and needs same-day medical attention. Orthostatic hypotension is a recognized effect, particularly at higher doses, and raises fall risk in older adults. Other commonly reported effects include dry mouth, dizziness, and next-day sedation, generally less pronounced than with mirtazapine at typical sleep doses. Trazodone should be used cautiously, or avoided, in patients on other serotonergic drugs (serotonin syndrome risk), those taking antihypertensives (additive blood pressure lowering), and anyone with a personal history of priapism.

Mirtazapine's most consistently reported issues at sleep doses are appetite increase, weight gain, and next-day grogginess. Its label also carries a rare warning about agranulocytosis (a dangerous drop in white blood cells); any fever, sore throat, or mouth ulcers during treatment should prompt urgent evaluation. Mirtazapine should be used cautiously in people with obesity, metabolic syndrome, or type 2 diabetes, since appetite stimulation can worsen glycemic control, and some patients report worsening restless legs symptoms.

Both drugs are contraindicated with monoamine oxidase inhibitors (MAOIs); label-recommended washout periods apply and should be confirmed with the prescriber or pharmacist rather than assumed. Combining trazodone with other serotonergic medications, or combining mirtazapine with other central nervous system depressants (opioids, benzodiazepines, alcohol), increases risk and requires clinical judgment rather than self-adjustment.

How trazodone and mirtazapine compare with FDA-approved sleep medications

Several medications carry an actual FDA indication for insomnia, and it is worth knowing where they sit relative to trazodone and mirtazapine before assuming an antidepressant is the right off-label choice.

Zolpidem (Ambien) and eszopiclone (Lunesta) are Schedule IV GABA-A modulators with FDA insomnia indications. They are generally more reliable than trazodone for shortening sleep-onset time in controlled comparisons, but they carry dependence potential, next-day psychomotor impairment, and a documented risk of complex sleep-related behaviors; the FDA has previously updated prescribing guidance across the benzodiazepine and Z-drug sedative-hypnotic class over these safety concerns. For someone with a substance-use history, trazodone or mirtazapine may be preferred specifically because neither carries scheduled-substance status.

Suvorexant (Belsomra) and lemborexant (Dayvigo) are dual orexin receptor antagonists with FDA insomnia indications. They work by suppressing wake-promoting signaling rather than by directly sedating, are not scheduled in the same restrictive way as older hypnotics, and are increasingly favored by sleep specialists for longer-term use, though they typically cost more than generic trazodone or mirtazapine.

Ramelteon (Rozerem) is an FDA-approved melatonin receptor agonist for sleep-onset insomnia, is not scheduled, and does not carry the priapism or weight-gain risks discussed above; its effect on sleep-onset time tends to be modest compared with GABA-A hypnotics. Over-the-counter melatonin supplements are not FDA-regulated as drugs, and independent testing has repeatedly found meaningful discrepancies between labeled and actual melatonin content in commercial products, which is one reason clinicians treat supplement dosing as unreliable compared with a regulated prescription product. Exact percentage figures from any single study should be confirmed against the primary source before being repeated as fact.

If sleep problems are driven by obstructive sleep apnea rather than primary insomnia, neither trazodone, mirtazapine, nor any of the above sleep medications treats the underlying cause. CPAP remains the standard first-line therapy for moderate to severe OSA, and mandibular advancement (oral appliance) devices are an accepted alternative for people who cannot tolerate CPAP or who have mild to moderate disease. Prescribing a sedating antidepressant to someone with undiagnosed OSA is a specific failure mode worth naming: sedation can blunt the arousal responses that normally interrupt an apneic event, so screening (for example with the STOP-BANG questionnaire or a home sleep apnea test) is reasonable before starting either drug in a patient who snores, has obesity, or reports unrefreshing sleep despite adequate time in bed.

Typical dosing and what changing doses does

Trazodone for sleep is usually started at a low dose, commonly in the 25 to 50 mg range at bedtime, with titration only if needed and under the prescriber's guidance. Doses used for depression (150 mg and above) are generally reserved for that indication and provide diminishing hypnotic benefit relative to their side-effect burden.

Mirtazapine for sleep is usually started at the lowest available strength, commonly 7.5 to 15 mg at bedtime. As noted above, higher antidepressant doses (30 to 45 mg) are often less sedating, not more, which is counterintuitive and worth discussing with the prescriber rather than assuming "more is more sedating."

This article does not provide individualized dosing instructions. Starting dose, titration, and duration of use should be set by the prescribing clinician based on the individual's diagnosis, other medications, and health history.

A practical note on duration and follow-up

Guideline bodies, including the American College of Physicians, have recommended cognitive behavioral therapy for insomnia (CBT-I) as a first-line approach for chronic insomnia disorder, ahead of medication, based on its durable benefit without the side-effect tradeoffs discussed above. Where medication is used, whether trazodone, mirtazapine, or an FDA-approved hypnotic, a reasonable practice is to reassess the plan at four to six weeks rather than continuing indefinitely by default, and to discuss whether CBT-I or another behavioral approach could reduce or replace the medication over time. Anyone experiencing a prolonged or painful erection, signs of infection while on mirtazapine (fever, sore throat, mouth ulcers), fainting, or worsening daytime function on either drug should seek prompt medical care rather than waiting for a scheduled follow-up.